Published in Cancer Weekly, March 28th, 2006
"With the initiation of these studies, we are taking an important step toward the clinic with a second compound from our E2F1 checkpoint pathway program, based on our alliance with Roche," said Stephen A. Hill, president and chief executive officer of ArQule. "If data from these studies with ARQ 171 are supportive, the next step in the development process for ARQ 171 will be the filing of an investigational new drug application."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.